Satvat Ali J. 4
4 · Coherus Oncology, Inc. · Filed Jun 9, 2026
Research Summary
AI-generated summary of this filing
Coherus Oncology (CHRS) Director Satvat Ali Receives Award
What Happened Satvat Ali J., a director of Coherus Oncology (CHRS), received equity awards on June 5, 2026: 30,000 restricted stock units (RSUs) and 60,000 derivative awards (option-like). Both grants show $0.00 paid on the Form 4 (company compensation awards rather than open-market purchases). Together the awards total 90,000 equity instruments subject to future vesting.
Key Details
- Transaction date: June 5, 2026; Form 4 filed June 9, 2026 (filed on time).
- Consideration: $0.00 reported for each grant (award/compensation, not a cash purchase).
- Award breakdown: 30,000 RSUs (F1) and 60,000 derivative awards (F2).
- Vesting: F1 — RSUs convert 1:1 to common shares and vest 100% on June 3, 2027, subject to continued service. F2 — underlying shares become exercisable/vest 100% on June 3, 2027, subject to continued service.
- Shares owned after the transactions: not specified in the provided filing details.
- Filing timeliness: Filed June 9, 2026 for a June 5 transaction — within the standard Form 4 reporting window.
Context These were compensation grants (awards), a routine form of insider compensation and not an open-market purchase or sale. The 30,000 RSUs will convert to shares at vesting; the 60,000 derivative awards give rights to acquire shares in the future if the recipient remains employed/serving through the vesting date. Such awards indicate expected future ownership potential but do not reflect an immediate purchase or sale.
Insider Transaction Report
- Award
Common Stock
[F1]2026-06-05+30,000→ 30,000 total - Award
Stock Option (Right to Buy)
[F2]2026-06-05+60,000→ 60,000 totalExercise: $1.45Exp: 2036-06-05→ Common Stock (60,000 underlying)
Footnotes (2)
- [F1]Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.
- [F2]The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date.